RY_SW01 / Jiangsu Renocell Biotech - LARVOL DELTA

Multi-center Phase I/II Clinical Study Protocol for the Safety, Tolerability and Efficacy of RY_SW01 Cell Injection in the Treatment of Systemic Sclerosis (ChiCTR) - P1/2 | N=81 | Recruiting | Sponsor: Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital

New P1/2 trial • Immunology • Scleroderma • Systemic Sclerosis

Phase I clinical study on the in vivo distribution and metabolic kinetic characterization of 89Zr-Oxine-RY_SW01 cell injection for the treatment of systemic sclerosis (ChiCTR) - P1 | N=8 | Recruiting | Sponsor: The First Hospital of Suzhou University; The First Hospital of Suzhou University

New P1 trial • Immunology • Scleroderma • Systemic Sclerosis

RY_SW01 Safety, tolerability and efficacy of Cellular Injection in the treatment of active lupus nephritis. Safety, Tolerability and Efficacy of Cellular Injection in the Treatment of Active Lupus Nephritis Multicenter Phase I/II Clinical Trial Protocol (ChiCTR) - P1/2 | N=69 | Recruiting | Sponsor: Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital

New P1/2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Jiangsu Ruiyuan Biotechnology Co., Ltd.'s drug clinical trial implied license application was accepted [Google translation] (new.qq.com) - "On April 24, according to the official website of CDE, Jiangsu Ruiyuan Biotechnology Co., Ltd. jointly applied for the drug 'RY_SW01 cell injection' and obtained implicit approval for clinical trials, acceptance number CXSL2500082....Public information shows that the drug 'RY_SW01 Cell Injection' is indicated for type 2 diabetic kidney disease."

New trial • Diabetic Nephropathy

89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Jiangsu Renocell Biotech Company

New P1 trial • Immunology • Scleroderma • Systemic Sclerosis

RY_SW01 Cell Injection Therapy in Systemic Sclerosis (clinicaltrials.gov) - P1/2 | N=81 | Recruiting | Sponsor: Jiangsu Renocell Biotech Company | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis

RY_SW01 Cell Injection Therapy in Systemic Sclerosis (clinicaltrials.gov) - P1/2 | N=81 | Not yet recruiting | Sponsor: Jiangsu Renocell Biotech Company

New P1/2 trial • Fibrosis • Immunology • Scleroderma • Systemic Sclerosis • IL6 • TNFA • TNFRSF1A

RY_SW01 Cell Injection Therapy in Active Lupus Nephritis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Jiangsu Renocell Biotech Company

New P2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • CXCL10